Literature DB >> 15386584

Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column.

F Péhourcq1, C Jarry, B Bannwarth.   

Abstract

A direct plasma injection liquid chromatographic method has been developed for the determination of a new triazole antifungal agent, voriconazole, using an internal surface reversed phase column. Therapeutic drug monitoring of voriconazole is relevant for patient management, especially in the case of drug-drug interaction. The method is easy to perform and requires 10 microL of a plasma sample. The chromatographic run time is less than 9 min using a mobile phase of 17:83 v/v acetonitrile-potassium dihydrogen phosphate buffer, 100 mM, pH 6.0 and UV detection at 255 nm. The fl ow rate was 1 microL/min. A linear response was observed over the concentration range 0.5-10 microg/mL (r2 = 0.977). A good accuracy (bias < or = 7.5%) was achieved for all quality controls, with intra-day and inter-day variation coefficients inferior to 6.7%. The lower limit of quantitation was 0.2 microg/mL, without interference of endogenous components. The stability of voriconazole in plasma stored at different temperatures was checked. Finally, the possibility of direct injection of plasma samples into the column permits a reduction in reagent consumption and in analytical steps, and hence in analytical error. 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15386584     DOI: 10.1002/bmc.383

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

1.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

3.  Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.

Authors:  I Fan Kuo; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-11

4.  Validated LC Method for the Estimation of Voriconazole in Bulk and Formulation.

Authors:  C N Patel; J B Dave; J V Patel; B Panigrahi
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

5.  Development and Validation of Stability Indicating RP-HPLC Method for Voriconazole.

Authors:  A B Khetre; P K Sinha; Mrinalini C Damle; R Mehendre
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

Review 6.  Assessment of greenness for the determination of voriconazole in reported analytical methods.

Authors:  Hemanth Kumar Chanduluru; Abimanyu Sugumaran
Journal:  RSC Adv       Date:  2022-02-28       Impact factor: 3.361

7.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yukihiro Hamada; Issei Tokimatsu; Hiroshige Mikamo; Masao Kimura; Masafumi Seki; Shunji Takakura; Norio Ohmagari; Yoshiko Takahashi; Kei Kasahara; Kazuaki Matsumoto; Kenji Okada; Masahiro Igarashi; Masahiro Kobayashi; Takahiro Mochizuki; Yoshifumi Nishi; Yusuke Tanigawara; Toshimi Kimura; Yoshio Takesue
Journal:  J Infect Chemother       Date:  2013-05-15       Impact factor: 2.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.